Stockscreener 앱 받기
1.89
2.07%
-0.04
시간 외 거래:
1.89
전일 마감가:
$1.93
열려 있는:
$1.94
하루 거래량:
399.81K
Relative Volume:
0.41
시가총액:
$278.53M
수익:
$72,500
순이익/손실:
$-45.96M
주가수익비율:
-2.7737
EPS:
-0.6814
순현금흐름:
$-44.56M
1주 성능:
-9.57%
1개월 성능:
-23.17%
6개월 성능:
+101.00%
1년 성능:
+46.51%
1일 변동 폭
$1.87
$2.04
1주일 범위
$1.87
$2.19
52주 변동 폭
$0.7984
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.89 | 284.42M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx Nv 주식(IFRX)의 최신 뉴스
InflaRx N.V. (IFRX) Options ChainYahoo Finance - Yahoo! Finance Canada
InflaRx to Host Virtual Capital Markets Day - Moomoo
Price to earnings forward of InflaRx N.V. – HAM:IF0 - TradingView
Inflarx N.v Stock Price Forecast. Should You Buy IFRX? - StockInvest.us
Needham Initiates InflaRx at Buy With $8 Price Target - Yahoo Finance
InflaRx at Cantor conference: renal pivot gains urgency - Investing.com
InflaRx at Cantor conference: renal pivot gains urgency By Investing.com - Investing.com UK
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
IFRX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesPretax Income Report - vinanet.vn
Farallon Capital Management Acquires New Position in InflaRx NV (IFRX) - GuruFocus
InflaRx (IFRX) Latest: Ends Down by 4.72% at $2.02 in the Latest Reading; Next Test: Price Remains Between $1.92 Support and $2.12 ResistanceLarge Cap Trends - vinanet.vn
InflaRx Announces Participation in September Investor Conferences - GlobeNewswire
Commodore Capital reports 5%+ stake in InflaRx (IFRX) - Stock Titan
IFRX Q2 2026 Earnings: Wider-than-Expected Loss Raises Stakes for Clinical ExecutionMargin Guidance - vinanet.vn
InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan
Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan
InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
Here's Why We're Not At All Concerned With InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
IFRX Q2 2026 Earnings: EPS Misses by 51.26% Yet Shares Advance 6.52%Earnings Sentiment Score - vinanet.vn
HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan
InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView
InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan
IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey
InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan
InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada
IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline FocusNext Quarter Guidance - vinanet.vn
InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView
No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net
InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
InflaRx N.V. (IFRX) Q1 2026 Earnings: Narrower Loss Beats Expectations, No Revenue ReportedPreliminary Results - dars.gov.et
Inflarx Nv (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):